What is Pharming?
Pharming Group N.V. is dedicated to the development and commercialization of innovative protein replacement therapies and precision medicines. The company's core mission revolves around addressing unmet medical needs within the rare disease patient community. By engaging with a diverse range of stakeholders, including investors and strategic partners, Pharming aims to foster growth and drive innovation in its specialized field. Their commitment extends to attracting top talent focused on enhancing patient outcomes.
How much funding has Pharming raised?
Pharming has raised a total of $117M across 2 funding rounds:
Debt
$17M
Debt
$100M
Debt (2015): $17M with participation from Oxford Finance and Silicon Valley Bank
Debt (2017): $100M led by OrbiMed
Key Investors in Pharming
Oxford Finance
Oxford Finance, established in 2002, is a specialty finance firm providing flexible financial solutions to healthcare and life sciences companies globally, indicating a focus on supporting biopharmaceutical innovation.
Silicon Valley Bank
Silicon Valley Bank (SVB) offers a comprehensive suite of financial services tailored for the technology and life sciences sectors, suggesting a strategic interest in Pharming's growth and operational financing needs.
OrbiMed
OrbiMed Advisors LLC is a prominent investment firm specializing in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health, highlighting their deep expertise in funding life sciences advancements.
What's next for Pharming?
With substantial enterprise-level backing and a recent strategic investment, Pharming is poised to accelerate its pipeline development and expand its commercial reach. The company's focus on rare diseases suggests a strategy centered on high-impact, niche therapeutic areas. Future endeavors will likely involve further clinical trial progression, potential regulatory submissions, and the scaling of manufacturing and distribution capabilities to serve a growing patient population. Continued collaboration with key financial partners and the life sciences ecosystem will be critical for sustained growth and market penetration.
See full Pharming company page
